Share

Landmark completion of comprehensive index of human proteins to be presented at New York Academy of Sciences

VACAVILLE, Calif.-- May 2, 2001--Large Scale Biology Corporation (Nasdaq: LSBC) is pleased to invite journalists and financial analysts to attend the first-ever scientific briefing on the recently completed inventory of proteins in the human body, known as the Human Protein Index(TM) (HPI(TM)). The HPI provides the first important baseline for determining the essential link between genes and the vast array of proteins in human health and disease. The briefing will be held on Wednesday, June 6, 2001 from 9:30 AM to 12:00 PM at the New York Academy of Sciences in New York City.

Dr. Leigh Anderson, chief scientific officer of LSBC commented, "This first version of the Human Protein Index heralds a new era in the study of human anatomy begun with the reawakening of interest in human physiology in the 1400's. For the first time, scientists have a meaningful way to relate the function of the broadest array of proteins to their roles in disease and treatment. In fact, many of the discovered proteins have not yet been described in scientific literature, and may indeed provide a fascinating, and much more holistic, viewpoint on human health and illness."

"LSBC is pursuing direct health applications of the HPI through an alliance with Biosite Diagnostics, in which we plan to select 2,000 - 5,000 protein targets to be used to create protein chips," said Robert Erwin, CEO of LSBC. "We believe protein chips represent the third, and foreseeably most important technology of proteomics alongside 2-D electrophoreses and mass spectrometry."

The conference will feature a distinguished panel of scientists who will discuss the historic, decades-long search for the human proteome, as well as how the Human Protein Index was developed, its initial findings, and its potential impact on medicine.

DATE: Wednesday, June 6, 2001

TIME: 9:30 AM - 12:00 PM Eastern

LOCATION: New York Academy of Sciences, 2 East 63rd Street, New York, NY

Journalists, financial analysts and investors can register to attend the meeting by calling Burns McClellan at (212) 213-0006. Space is limited, and reservations will be accepted on a first-come basis. During the meeting, a simultaneous audio webcast with slide presentation will be available by accessing Large Scale Biology's internet site (http://www.lsbc.com). Alternatively, within one hour following the presentation, a recording will be available for 30 days on the Large Scale Biology website.

Large Scale Biology Corporation is an industry leader in identifying and characterizing proteins in all types of biological samples for the discovery and development of new and more effective disease diagnostics, therapeutics, vaccines and agricultural products. Large Scale Biology has pioneered the development and application of many of the tools now considered to be state-of-the-art in genomics and proteomics. Corporate offices and the Genomics and Antigenics divisions are headquartered in Vacaville, California, the Company's Proteomics subsidiary is located in Germantown, Maryland; and the Company's bioprocessing and manufacturing facilities are located in Owensboro, Kentucky. For more information about LSBC, visit the Company's website at www.lsbc.com.

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on our current plans, expectations, estimates, and projections and management's beliefs about our future performance. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates" or variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and which may cause our actual results and performance to differ materially from those expressed or forecasted in any such forward-looking statements. For a further list and description of such risks and uncertainties see the reports filed by Large Scale Biology Corporation with the Securities Exchange Commission. Unless required by law, Large Scale Biology Corporation undertakes no obligation to update publicly any forward-looking statements.

Contact: Burns McClellan 212-213-0006
Kathy L. Jones, Ph.D. (Media)
Raj Punwaney, M.D., M.B.A. (Investors)

Share

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.